Galectin-3 Binding Molecule for Atherosclerosis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating inflammatory diseases, particularly atherosclerosis, lack effective and targeted therapies with low side effects, as they often rely on luminal stenosis measurements that fail to identify high-risk patients and can lead to severe events.
Innovation Solution
Development of a specific binding molecule that specifically binds to galectin-3 protein, comprising a variable heavy domain and a variable light domain with high amino acid sequence identity, which is used to create monoclonal antibodies or scFv fragments for targeted therapy and diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If luminal stenosis measurements are used for diagnosis, then atherosclerosis can be detected, but high-risk patients cannot be identified and severe events occur
Solution Approach 1:
The patent changes the diagnostic parameter from luminal stenosis measurement to galectin-3 protein detection. By detecting the presence and level of galectin-3 protein in blood samples, the invention enables identification of high-risk patients before severe events occur, improving both diagnosis accuracy and patient risk identification reliability.
Solution Approach 2:
The patent introduces galectin-3 protein as an intermediary marker between atherosclerosis pathology and clinical events. This protein serves as a detectable mediator that reflects disease activity and risk, allowing for earlier and more accurate patient identification without requiring direct measurement of luminal stenosis.
2Productivity
If non-specific therapies are used for inflammatory diseases, then treatment can be provided, but side effects are severe and therapy is not sustained
Solution Approach 1:
The patent applies local quality by designing monoclonal antibodies that specifically target galectin-3 protein in the context of atherosclerosis. This specificity ensures that the therapeutic effect is localized to the disease mechanism rather than providing broad non-specific immunosuppression, thereby reducing harmful side effects while maintaining therapy effectiveness.
Solution Approach 2:
The patent uses monoclonal antibodies as molecular copies that precisely replicate the function of neutralizing galectin-3. These engineered protein copies provide sustained therapeutic action by continuously binding and neutralizing the target protein, offering controlled therapy with reduced side effects compared to non-specific treatments.
3Object-affected harmful factors
If targeted therapy against galectin-3 is developed, then side effects are reduced and therapy is sustained, but the binding molecule must be highly specific
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional domains: the variable region (VH and VL) that provides specific galectin-3 binding, and the constant region that provides effector functions. This segmentation allows independent optimization of binding specificity in the variable region while maintaining controlled therapeutic activity through the constant region, reducing side effects.
Solution Approach 2:
The patent changes the binding parameters by engineering the variable domains of the monoclonal antibody to achieve high affinity and specificity for galectin-3. Through parameter optimization of the binding interface, the invention achieves sustained targeted therapy with minimal off-target effects, resolving the contradiction between specificity requirements and therapeutic safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The specific binding molecule effectively targets galectin-3 protein, providing a sustained and controlled therapeutic approach with reduced side effects, enabling improved diagnosis and treatment of inflammatory diseases and atherosclerosis by specifically binding to galectin-3 protein with high affinity.
Implementation Method 1
a specific binding molecule which specifically binds to galectin-3 protein
Data Source
AI summary
A specific binding molecule is provided which binds to galectin-3 protein, methods of their production and methods of use.